|1.||Zavadenko, N N: 6 articles (01/2010 - 01/2004)|
|2.||Celani, M G: 4 articles (01/2006 - 01/2000)|
|3.||Righetti, E: 4 articles (01/2006 - 01/2000)|
|4.||Ricci, S: 4 articles (01/2006 - 01/2000)|
|5.||Voronina, T A: 3 articles (04/2010 - 01/2000)|
|6.||Guzilova, L S: 3 articles (01/2010 - 01/2008)|
|7.||Cantisani, A T: 3 articles (01/2006 - 01/2000)|
|8.||He, Zhi: 2 articles (05/2014 - 06/2008)|
|9.||Levykh, A E: 2 articles (04/2014 - 07/2013)|
|10.||Mamchur, V I: 2 articles (04/2014 - 07/2013)|
|1.||Myoclonus (Nocturnal Myoclonus)
01/01/2006 - "He presented with severe myoclonus, which was resistant to conventional therapy and dramatically improved after administration of 12-18 gm/die piracetam. "
01/01/2004 - "The action myoclonus, which severely impaired her daily life, was markedly improved by administration of piracetam, a drug reportedly useful for myoclonus of cortical origin. "
10/01/2000 - "In the placebo-controlled double-blind crossover trial of piracetam conducted in the UK, there was a significant improvement in cortical myoclonus. "
07/01/1999 - "Although there is evidence from case reports and clinical trials of the therapeutic efficacy of piracetam in patients with skeletal myoclonus of various causes, to our knowledge this is the first report indicating the beneficial effect of piracetam monotherapy on post-ischaemic palatal myoclonus."
10/01/2000 - "These results show that piracetam has a beneficial use in clinics for severe myoclonus patients when it is combined with anti-epileptic drugs, demonstrating an improvement in the myoclonus and QOL of patients."
12/01/2000 - "The data suggest that the overall efficacy of piracetam in secondary stroke prophylaxis is not as good as that of ASA but that piracetam is better tolerated. "
12/01/1997 - "Additional analyses within this subgroup, confined to 360 patients with moderate and severe stroke (initial Orgogozo scale score < 55), showed significant improvement on piracetam in both outcomes (P < .02). "
03/01/1999 - "This was a multicenter double-blind trial in 927 patients to determine whether, compared with placebo, piracetam improved outcome when given within 12 hours of the onset of acute ischemic stroke, confirmed by computed tomography within 24 hours of admission (but not necessarily prior to treatment). "
01/01/2012 - "Piracetam has neuroprotective and antithrombotic effects that may help to reduce death and disability in people with acute stroke. "
01/01/2009 - "Efficacy of omaron (a combination of piracetam 400 mg and cinnarizin 25 mg) has been studied 3 months after stroke in 90 post-stroke patients. "
|3.||Alzheimer Disease (Alzheimer's Disease)
01/01/2010 - "Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam."
02/01/1993 - "Preclinical research suggests that piracetam (a nootropic drug) may improve cognitive functions, but previous studies have failed to demonstrate a clear benefit for the treatment of Alzheimer's disease (AD). "
11/01/2003 - "However, for patients with probable Alzheimer's disease, as well as for adults with age-associated memory impairment, there is no clear-cut support for a mnemonic benefit of piracetam. "
05/01/2002 - "However, for patients with probable Alzheimer's disease, as well as for adults with age-associated memory impairment, there is no clear-cut support for a mnemonic benefit of piracetam. "
05/28/2000 - "This treatment could be effective even in Alzheimer's disease, in case of more pronounced cognitive decline, longer duration of the illness, and in case of former piracetam treatment as well. "
|4.||Vertigo (Positional Vertigo)
03/01/1999 - "Piracetam has been shown to be effective in vertigo of both central and peripheral origin. "
01/01/2009 - "[Efficacy of piracetam in vertigo]."
01/01/1980 - "The efficacy of piracetam in vertigo. "
03/01/1999 - "The usual dosage of piracetam in vertigo is 2.4-4.8 g daily. "
03/01/1999 - "Piracetam decreases the frequency but probably not the severity of exacerbations in patients with chronic or recurrent vertigo. "
01/01/1982 - "Both piracetam and ginseng treatment provided good protection against electroshock stress when compared to the untreated mice; fighting scores, incidence of tonic convulsion and mortality were significantly less in the treated groups. "
04/01/2010 - "Piracetam is a nonprescription noot ropic drug designated by the FDA as an orphan drug for myoclonic seizures. "
09/01/2004 - "Generally, piracetam exhibits no or only moderate anticonvulsant properties against generalized tonic or clonic seizures. "
10/01/1999 - "Furthermore, we tested acute piracetam effects on developed kindling seizures, the learning deficit and potentiation effects. "
12/01/1997 - "The effect of the nootropic drug piracetam (100 mg/kg) on kindled seizures, kindling-induced learning deficits, and histological alterations due to changes in central excitability was investigated in Wistar rats. "
|2.||Nootropic Agents (Nootropics)
|4.||Anticonvulsants (Antiepileptic Drugs)
|6.||Valproic Acid (Valproate, Semisodium)
|10.||4-amino-3-phenylbutyric acid (phenibut)
|1.||Language Therapy (Language Training)
|2.||Hormone Replacement Therapy (Therapy, Hormone Replacement)
|3.||Speech Therapy (Therapy, Speech)